Development stage healthcare delivery company HOPE Therapeutics Inc, a subsidiary of NRx Pharmaceuticals Inc (Nasdaq:NRXP), announced on Monday that it has appointed BTIG, a financial services company specialising in investment banking, institutional trading, research and related brokerage services, as its financial advisor.
The scope of the engagement includes advisory and assistance in evaluating strategic and financing options available to the company and identification, evaluation and negotiation of potential acquisition targets for the HOPE network of clinics, as well as equity and debt financing structures.
The company recently announced execution of an agreement for USD27m in funding for HOPE clinic acquisition. Upon closing of the first tranche of the anticipated financing, the company intends to leverage the investment with proposed bank debt and similar instruments to fund its initial rollup of Interventional Psychiatry Clinics.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA